UK-based medical technology company Origin Sciences has launched the new OriCol microbiome research kit, developed for use in gut microbiome research.
Origin is focused on developing new sampling devices and diagnostics for the stratification of patients with gastrointestinal diseases.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The company noted that understanding the gut microbiome has the potential to change how a range of diseases and illnesses are treated, and in particular gastrointestinal diseases and related cancers.
The microbiome research kit is an effective tool for sampling rectal mucosa, which can be used to study the gut microbiome and how it correlates with factors such as treatments, diet and disease.
Mucosal samples obtained using the kit comprises an established community of bacteria inhabiting the gut, including the same spectrum of bacteria as stool samples.
According to the company, mucosal samples collected using OriCol research kit show an increased bacterial diversity and an enrichment of mucosal associated phyla.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataOrigin Sciences CEO Paul Weinberger said: "The microbiome is a growing area of research interest for the life sciences and pharmaceutical industries and has seen significant investment.
"However, it is a particularly challenging area to work in, and new tools and techniques are required.
"By using the OriCol microbiome research kit, researchers can get better data, and improve their research, while also making sample collection less of a challenge for patients and researchers."
In 2014, the company launched OriCol, a sampling device for investigating gastrointestinal (GI) disease.
The device, which received CE Mark approval, collects biologically informative samples containing a range of biomarkers to enable clinical analysis and research into GI conditions.
